In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells, and chemotherapy.

被引：0
|
作者：
Gladue, R. P. [1 ]
Cole, S. H. [1 ]
Donovan, C. [1 ]
Paradis, T. [1 ]
Alpert, R. [1 ]
Natoli, E. [1 ]
Bedian, V. [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103S / 103S
页数：1
相关论文
共 50 条
  • [1] Surface expression of CD40 on human melanoma and the direct in vitro growth effects of an anti-CD40 agonist antibody, CP-870,893
    Kalbasi, A.
    Chmielowski, B.
    Ribas, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 223 - 224
  • [2] CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893
    Kalbasi, Anusha
    Fonsatti, Ester
    Natali, Pier Giorgio
    Altomonte, Maresa
    Bertocci, Erica
    Cutaia, Ornella
    Calabro, Luana
    Chiou, Michael
    Tap, William
    Chmielowski, Bartosz
    Maio, Michele
    Ribas, Antoni
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 810 - 816
  • [3] A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer.
    Beatty, G. L.
    Chiorean, E. G.
    Torigian, D. A.
    Teitelbaum, U. R.
    Sun, W.
    Fly, K. D.
    Huhn, R. D.
    Vonderheide, R. H.
    O'Dwyer, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
    Ronald P. Gladue
    Timothy Paradis
    Susan H. Cole
    Carol Donovan
    Robin Nelson
    Robbin Alpert
    Joe Gardner
    Ed Natoli
    Eileen Elliott
    Richard Shepard
    Vahe Bedian
    Cancer Immunology, Immunotherapy, 2011, 60 : 1009 - 1017
  • [5] The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
    Gladue, Ronald P.
    Paradis, Timothy
    Cole, Susan H.
    Donovan, Carol
    Nelson, Robin
    Alpert, Robbin
    Gardner, Joe
    Natoli, Ed
    Elliott, Eileen
    Shepard, Richard
    Bedian, Vahe
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (07) : 1009 - 1017
  • [6] Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
    Vonderheide, Robert H.
    Flaherty, Keith T.
    Khalil, Magi
    Stumacher, Molly S.
    Bajor, David L.
    Hutnick, Natalie A.
    Sullivan, Patricia
    Mahany, J. Joseph
    Gallagher, Maryann
    Kramer, Amy
    Green, Stephanie J.
    O'Dwyer, Peter J.
    Running, Kelli L.
    Huhn, Richard D.
    Antonia, Scott J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) : 876 - 883
  • [7] Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    Vonderheide, R. H.
    Flaherty, K. T.
    Khalil, M.
    Stumacher, M. S.
    Bajor, D. L.
    Gallagher, M.
    Sullivan, P.
    Mahaney, J. J.
    O'Dwyer, P. J.
    Huhn, R. D.
    Antonia, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 101S - 101S
  • [8] Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
    Vonderheide, Robert H.
    Burg, Jennifer M.
    Mick, Rosemarie
    Trosko, Jennifer A.
    Li, Dongguang
    Shaik, M. Naveed
    Tolcher, Anthony W.
    Hamid, Omid
    ONCOIMMUNOLOGY, 2013, 2 (01):
  • [9] Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
    Erica L Carpenter
    Rosemarie Mick
    Jens Rüter
    Robert H Vonderheide
    Journal of Translational Medicine, 7
  • [10] Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
    Carpenter, Erica L.
    Mick, Rosemarie
    Rueter, Jens
    Vonderheide, Robert H.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7 : 93
12345